Rubius Therapeutics Inc. (RUBY) saw an uptrend of 6.91% in the recent trading with $22.58 being its most recent. The current price level -41.67% lower than the highest price of $38.71 marked by the stock while trading over the past 52-weeks, whereas it is 437.62% higher than the lowest price of $4.20 the company dropped to over past 52-weeks. The latest news story on RUBY appeared in GlobeNewswire under the title “Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy” on Jul-15-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -14.26% below one month high and is +8.04% above of the lowest during that time. Looking into the simple moving average, Rubius Therapeutics Inc. (RUBY)’s stock stands at a SMA-50 of $24.83 while that of 5-day is reading $22.25.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and RUBY’s SMA-200 as of now is $15.74.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 6 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.20 for the stock.
Rubius Therapeutics Inc. Earnings – What Happened With RUBY
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
RUBY – Rubius Therapeutics Inc. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 82.31 million. RUBY does have institutional investors; and they hold 98.20% of the stock.
Rubius Therapeutics Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares. On the other hand, RUBY declared 150,441 shares have been sold in 5 insider transactions over the past three months.
Currently, the stock has been recommended as Moderate Buy by 6 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.20 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Rubius Therapeutics Inc. was 6.52 while posting a debt to equity ratio of 0.25. The count was 76.09 for long-term debt to equity ratio.
Rubius Therapeutics Inc.’s return on equity, or ROE, is -78.70%, compared to the industry average of -38.26% for Healthcare – Biotechnology. Although this indicates that RUBY fails to use its equity well, the metric will vary significantly depending on the industry.
Technical Analysis of Rubius Therapeutics Inc. (NASDAQ:RUBY) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Rubius Therapeutics Inc. (RUBY), we notice that the stock’s 20-day average volume is at 481,160 shares. Medium term indicators at an average of 50% are spotting the stock at Buy with its 50-day average volume of 564,770 shares. And to end, RUBY’s 100-day average volume is 1,354,781 shares with 50% of the long-term indicators pointing towards Buy for the stock.